Drug use evaluation of nirmatrelvir/ritonavir in three primary care centres during 2022
DOI:
https://doi.org/10.30827/ars.v64i4.28499Keywords:
COVID-19; nirmatrelvir/ritonavir; atención primaria; estudio de utilización de medicamentos; efectividadAbstract
Introduction: Nirmatrelvir/ritonavir (Paxlovid®) is the only oral treatment authorized in Europe to treat COVID-19 disease in adults who do not require supplemental oxygen and who are at high risk for progression to severe COVID-19.
It is available in Spain after validation due to the profile of interactions and warnings for use.
The objective is to determine effectiveness, safety and management of interactions.
Method: Retrospective study of all patients on validated nirmatrelvir/ritonavir treatment at three urban health centres during 2022. Effectiveness was the proportion of participants without COVID-19-related hospitalization or death from any cause through day 28.
Results: 24 patients were analyzed. It was considered effective in 23 (95.8 %). More than 80 % of patients presented potential interaction with the concomitant medication, recommending the temporary suspension of medications, highlighting simvastatin and metamizole.
Conclusions: Nirmatrelvir/ritonavir has been considered effective but difficult to manage in polymedicated polypathological patients.
Downloads
References
European Medicine Agency. Consultada el 02/03/2023. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/paxlovid
Ministerio de Sanidad. Consultada el 02/03/2023. Disponible en: https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=5624
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM; EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022; 386(15):1397-1408. doi: 10.1056/NEJMoa2118542.
Canal Salut Generalitat Catalunya. Consultada el 02/03/2023. Disponible en: https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/professionals/recomanacions-inici-seguiment-tractament-paxlovid.pdf
Reis S, Metzendorf MI, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev. 2022;20(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein LH, Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2023;76(3):e342-e349. doi: 10.1093/cid/ciac443.
Agencia Española de Medicamentos y Productos Sanitarios. Criterios para valorar la administración de las nuevas alternativas terapéuticas antivirales frente a la infección por SARS-CoV-2. Versión 3. 30 de marzo de 2022. Consultada el 20/4/2023. Disponible en: https://www.aemps.gob.es/medicamentos-de-uso-humano/acceso-a-medicamentos-en-situaciones-especiales/criterios-para-valorar-la-administracion-de-las-nuevas-alternativas-terapeuticas-antivirales-frente-a-la-infeccion-por-sars-cov-2/
Registre de casos de COVID-19 a Catalunya per àrea bàsica de salut i sexe. Portal de dades obertes de la Generalitat. Consultada el 31/03/2023. Disponible en: https://analisi.transparenciacatalunya.cat/
Sistema d’Informació per a la Vigilància d’Infeccions a Catalunya. COVID-19. Consultada el 31/03/2023. Disponible en: https://sivic.salut.gencat.cat/covid?ftemporada=12®io=3&ftipusdada=2
EMA. Molnupiravir. Consultada el 31/03/2023. Disponible en: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/lagevrio
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 José Miguel Sotoca Momblona, Marina Rovira-Illamola
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
0
